Trinity Biotech Files Routine 6-K Report
Ticker: TRIB · Form: 6-K · Filed: Dec 17, 2024 · CIK: 888721
| Field | Detail |
|---|---|
| Company | Trinity Biotech PLC (TRIB) |
| Form Type | 6-K |
| Filed Date | Dec 17, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $1,000,000, $0.0109 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-k, routine-report
TL;DR
Trinity Biotech filed its monthly 6-K, just keeping the SEC updated.
AI Summary
Trinity Biotech plc filed a Form 6-K on December 17, 2024, for the month of December 2024. The company, based in Ireland, is a foreign private issuer and is required to file reports under the Securities Exchange Act of 1934. This filing does not appear to contain specific financial or operational updates beyond its routine reporting status.
Why It Matters
This filing indicates Trinity Biotech plc is fulfilling its ongoing reporting obligations as a foreign private issuer with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — This is a routine filing by a foreign private issuer and does not contain new material information that would typically impact risk.
Key Players & Entities
- TRINITY BIOTECH PLC (company) — Registrant
- 0000888721 (company) — Central Index Key
- 2835 (company) — Standard Industrial Classification Code
- IDA Business Park, Bray, County Wicklow, Ireland (company) — Principal Executive Office Address
- 3 Rock Road, Sandyford Industrial Estates, Dublin, Ireland (company) — Mail Address
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information which the issuer makes or is required to make public in its home country.
When was this specific Form 6-K filed?
This Form 6-K was filed on December 17, 2024.
What period does this Form 6-K report cover?
This Form 6-K is for the month of December 2024.
Is Trinity Biotech plc a US-based company?
No, Trinity Biotech plc is identified as a foreign private issuer with its principal executive office in Ireland.
Does this filing indicate a change in reporting status (e.g., switching from 20-F to 40-F)?
The filing indicates that Trinity Biotech plc files annual reports under cover of Form 20-F, not Form 40-F.
Filing Stats: 379 words · 2 min read · ~1 pages · Grade level 13.2 · Accepted 2024-12-17 16:56:19
Key Financial Figures
- $1,000,000 — he Company may sell up to an additional $1,000,000 of American Depositary Shares ("ADSs"),
- $0.0109 — Company's A Ordinary Shares, par value $0.0109 per share, from time to time, through C
Filing Documents
- zk2432467.htm (6-K) — 17KB
- exhibit_5-1.htm (EX-5.1) — 79KB
- image00001.jpg (GRAPHIC) — 17KB
- image00003.jpg (GRAPHIC) — 15KB
- image00004.jpg (GRAPHIC) — 89KB
- 0001178913-24-004000.txt ( ) — 264KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TRINITY BIOTECH PLC Trinity Biotech plc (Registrant) By: /s/Louise Tallon Louise Tallon Chief Financial Officer Date: December 17, 2024